ARTICLES

Tetrabutylammonium Fluoride-Promoted Hydrothiolation of α-(Trifluoromethyl)styrenes with Thiophenols

  • Mei Zhang ,
  • Man Chen ,
  • Yu Chen ,
  • Qiuli Yao ,
  • Anjun Wang , *
Expand
  • Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, School of Pharmacy, Zunyi Medical University, Zunyi, Guizhou 563000

† These authors contributed equally to this work.

Received date: 2025-12-19

  Revised date: 2026-02-14

  Online published: 2026-04-21

Supported by

Zunyi City Science and Technology Plan Project (Zun City Kehe HZ character [2023]169)

Guizhou Province Science and Technology Plan Project (Guizhou Science Platform talent [2021]1350-005)

Science and Technology Department of Guizhou Province (QKHPTRC-CXTD[2022]-012)

Abstract

The trifluoromethyl and thioether groups are widely employed in the design of drug molecules. A hydrothiolation reaction of α-(trifluoromethyl)styrenes with thiophenols under solvent-free conditions is reported, which is promoted by tetrabutylammonium fluoride [TBAF, 1 mol/L in tetrahydrofuran (THF)]. This strategy features simple operation, mild reaction conditions, excellent functional group tolerance, and high chemoselectivity. The method demonstrates high atom economy, affording the target products in up to 95% yield, thus providing a concise and efficient alternative approach for the synthesis of β-trifluoromethyl thioethers.

Cite this article

Mei Zhang , Man Chen , Yu Chen , Qiuli Yao , Anjun Wang . Tetrabutylammonium Fluoride-Promoted Hydrothiolation of α-(Trifluoromethyl)styrenes with Thiophenols[J]. Chinese Journal of Organic Chemistry, 2026 , 46(6) : 2346 -2357 . DOI: 10.6023/cjoc202512026

三氟甲基(CF3)因其独特的性质——包括强吸电子效应、高亲脂性及优异的代谢稳定性——在药物分子设计中备受关注. 将CF3引入候选药物分子中, 有望显著提高其与靶蛋白结合的选择性、增强膜渗透性, 并改善体内的代谢稳定性[1]. 在新药研发的驱动下, 过去十年间, 研究人员利用各类含有三氟甲基化试剂, 在将CF3直接引入有机分子方面开展了大量工作[2]. 到目前为止, 发展高效、简洁的创新合成方法, 以构建结构新颖的含三氟甲基分子, 依然受到了广泛的关注.
硫醚是一类重要的结构单元, 广泛存在于多种生物活性分子与天然产物中[3]. 同时也存在一些上市药物中, 如抗哮喘药孟鲁司特(Montelukast)[4]、抗生素青霉素(Penicillin)[5]、抗真菌药布托康唑(Butoconazole)[6]、抗病毒药奈非那韦(Nelfinavir)[7]、降血脂药物丙丁酚(Probucol)[8]以及抗溃疡药雷尼替丁(Ranitidine)[9]等(图1). 硫醚还可以进行多种化学转化, 如可以氧化成亚砜、砜[10]. 除此之外, 将硫醚离子化后可以作为优异的离去基团, 从而发生各种反应, 这一性质可以通过其转化为张新刚试剂(3,3-二氟烯丙基锍盐)得到了具体体现[11]. 近年来, 芳基硫醚因其在药物化学中的重要应用而受到广泛关注, 相应的C—S键构建方法不断发展. 2023年, 李金恒课题组[12]报道了一种Ni催化的自由基还原交叉偶联策略构建烷基芳基硫醚, 将特定硫源(如含三氟甲基芳基硫代磺酸酯类前体)与卤代烃耦合, 实现C—S键组装, 但此策略依赖过渡金属催化. 2025年, 罗德平团队[13]报道了基于以对醌甲基作为亲电体的硫醇加成策略, 在无金属条件下高化学选择性合成芳基硫醚. 随后, 碱促进的硫醇-烯反应同样实现了在无金属条件下高效构建C—S键[14]. 随着含氟基团在药物分子中的广泛应用, 三氟甲硫基等含氟硫醚的构建也受到关注, 例如通过Ir催化亚砜脱氧反应实现三氟甲基硫醚的合成[15].
图1 含硫醚结构的药物分子

Figure 1 Drug molecules containing thioether structures

在贺春阳课题组[16]前期的工作中, 合成了一些含氟喹啉和喹啉酮衍生物, 其中的一些结构对Huh-7、A549和SK-hep-1等癌细胞表现出显著的抗肿瘤活性. 为了进一步对目标分子进行结构优化, 获得活性更加优秀的分子, 我们设想将先导分子之中连接CF3的脂肪链中一个亚甲基(CH2), 替换为硫醚(-S-) (Scheme 1a). 目前实现这类分子合成的方法主要有以下两种: 2024年, 曹松课题组[17]报道了1,5-二氮杂双环[4.3.0]壬-5-烯(DBN)促进的氢硫醇化反应, 实现了α-(三氟甲基)烯与苯硫醇的直接加成(Scheme 1, b-1), 但是这一策略对于含有喹啉酮的底物并不适用. 2025年, 涂海勇课题组[18]发展了一种无金属和催化剂的溶剂控制法用于合成不同类型的含氟硫醚, 其中使用二芳基二硫醚作为硫源合成β-三氟甲基硫醚, 对含氮杂环的烯烃并没有进行考察(Scheme 1, b-2). 鉴于以上方法存在的局限性, 因此, 发展一种新的反应体系以进一步拓展这一结构单元是十分必要的. 本研究中, 我们报道了一种在无需额外添加溶剂条件下, 四丁基氟化铵(TBAF)促进的α-(三氟甲基)苯乙烯与硫酚的氢硫醇化反应. 该策略操作简单、条件温和, 并显示出优异的官能团耐受性和化学选择性. 为合成β-三氟甲基硫醚类化合物提供了另一种简洁、高效的途径.
图式1 分子设计以及β-三氟甲基硫醚的合成方法

Scheme 1 Molecular design and synthesis methods of β-tri- fluoromethyl sulfide

1 结果与讨论

选择对甲基苯硫酚(1a)和4-甲氧基-α-(三氟甲基)苯乙烯(2a)为模板底物, 系统考察了碱、四氢呋喃(THF)、时间、反应气氛等对氢硫醇化反应的影响(Table 1).
表1 反应条件优化的代表性结果a,b

Table 1 Representative results for the optimization of reaction conditions

Entry Base (x equiv.) Time/h Atmosphere Yield/%
1 K2CO3 (0.5) 12 Ar —
2 Et3N (0.5) 12 Ar —
3 KF (0.5) 12 Ar —
4 CsF ( 0.5) 12 Ar —
5 TMAF (0.5) 12 Ar Trace
6c TBAF•3H2O (0.5) 12 Ar 90
7 TBAF•3H2O (0.5) 12 Ar 91
8 TBAF (0.5) 12 Ar 95 (91)
9 DBN (0.5) 12 Ar 89
10 DBU (0.5) 12 Ar 92
11 TBAF (1.0 ) 12 Ar 86
12 TBAF (0.4) 12 Ar 90
13 TBAF (0.3) 12 Ar 91
14 TBAF (0.2) 12 Ar 89
15 TBAF (0.1) 12 Ar 45
16 — 12 Ar —
17 TBAF (0.5) 10 Ar 79
18 TBAF (0.5) 12 Air 61

a Reaction conditions (unless otherwise specified): 1a (0.2 mmol, 1.0 equiv.), 2a (0.3 mmol, 1.5 equiv.), base (1.0 mol/L in THF), room temperature. b NMR yield determined by 19F NMR using fluorobenzene as internal standard and number in parenthesis is yield of isolated product. c Without THF.

首先考察了在室温、氩气保护条件下, 一系列0.5 equiv.的无机碱和有机碱参与反应12 h后对反应产率的影响(Table 1, Entry 1~10). 结果显示, 以K2CO3、Et3N、KF、CsF为碱时, 未见有痕量目标产物3a (Table 1, Entry 1~4). 使用四甲基氟化铵(TMAF)作为碱时, 可得痕量目标产物(Table 1, Entry 5). 当改用TBAF体系时, 无论是使用固体TBAF•3H2O还是TBAF•3H2O (1.0 mol/L in THF), 均能以优异的产率(90%~91%)得到目标产物3a (Table 1, Entry 6~7); 当将TBAF (1.0 mol/L in THF)作为碱时, 产物产率显著提高至95% (Table 1, Entry 8). 同时, 对强有机碱DBN和1,8-二氮杂双环[5.4.0]十一碳-7-烯(DBU)进行了考察, 二者同样能很好地促进反应, 产率分别为89%和92% (Table 1, Entry 9~10), 但略低于将TBAF (1.0 mol/L in THF)作为碱时的产率. 鉴于TBAF (1.0 mol/L in THF)表现最佳, 进一步考察了它的用量对反应产率的影响. 实验结果表明, 当加入1.0 equiv. TBAF (1.0 mol/L in THF), 反应12 h后, 通过19F NMR分析测得产物3a的产率为86% (Table 1, Entry 11); 当TBAF用量为0.5 equiv.时反应效果最佳, 产率高至95% (Table 1, Entry 8); 之后, 随着TBAF用量的减少, 产物产率逐渐下降(Table 1, Entries 12~15). 但在0.2 equiv. TBAF存在下, 依然能够以89%的收率得到目标产物(Table 1, Entry 14), 然而当TBAF用量减少到0.1 equiv.时, 产率降低到45% (Table 1, Entry 15). 当不再添加TBAF时, 则反应基本不发生(Table 1, Entry 16). 其次, 在拟定的TBAF体系下, 进一步考察了反应时间对产率的影响, 发现反应时间从12 h缩短至10 h, 产率就从95%降低至79% (Table 1, Entry 17), 因此12 h为最佳反应时长. 当反应暴露在空气中时, 产率亦有所下降, 仅能得到61%的目标产物(Table 1, Entry 18).
综上, 在氩气保护下, 以0.5 equiv.的TBAF (1.0 mol/L in THF)为碱, 于室温下反应12 h, 能以最优反应效果获得目标产物.
在最优反应条件下, 首先考察了该反应对不同α-(三氟甲基)苯乙烯类底物的普适性(Table 2). 当苯环上连有烷氧基或烷基等给电子基团时, 能以62%~87% 的收率得到目标产物(Table 2, 3a~3d). 苯环被卤素取代时也能获得64%的收率(Table 2, 3e). 对于含氨基的取代基, 二苯氨基(NPh₂)可获得91%的收率(Table 2, 3f), 苯环上连有吗啉基的产率则为72% (Table 2, 3g). 而当苯环上取代基为Ph时, 产率可达92% (Table 2, 3h). 苯环上的三甲基硅基(SiMe3)表现出明显的给电子效应, 降低了烯烃双键的亲电性, 导致反应活性下降, 在该条件下产物收率仅为51% (Table 2, 3i). 苯环上含有未保护的羧基(COOH)和醛基(CHO), 反应仍能顺利进行, 并以56%~60%的中等收率获得目标产物(Table 2, 3j~3k). 值得注意的是, CF3的吸电子诱导效应增强了烯烃双键的亲电性, 有效避免了硫醇负离子对羰基的亲核加成, 使得反应体系对含有酮基(3l)、酰胺(3m)及内酰胺(3n)官能团的底物展现出优异的兼容性, 产率高达81%~95% (Table 2, 3l~3n). 有趣的是, N-甲基保护的衍生物3n分离收率可达95%, 而对于NH未保护的喹啉酮类底物3o的产率仅为55%, 得益于3n的甲基通过提供电子和减少质子化的干扰, 使得氮原子更活跃, 增强了反应的亲核性和稳定性(Table 2, 3n~3o). 随后, 进一步研究了其他含氮杂环结构的底物. 喹啉和吡啶类在该体系中表现良好, 产物收率在61%~78%之间(Table 2, 3p~3s); 嘧啶类和噻唑类底物同样适用, 以56%和51%的中等收率获得目标化合物(Table 2, 3t~3u). 最后, 考察了含氧和硫的杂环底物对反应体系的兼容性, 苯并呋喃环衍生物的收率为54% (Table 2, 3v); 香豆素类底物也能顺利反应, 以66%的收率得到目标产物(Table 2, 3w); 苯并噻吩环衍生物则为81% (Table 2, 3x). 其中, 嘧啶、噻唑、呋喃等杂环骨架的电子效应干扰或减弱了CF3对烯烃的亲电活化, 以及杂环的空间位阻不利于硫负离子的亲核进攻, 均导致反应产率降低.
表2 底物普适性考察a,b

Table 2 Investigation of substrate scope

a Reaction conditions (unless otherwise specified): 1a (0.2 mmol, 1.0 equiv.), 2 (0.3 mmol, 1.5 equiv.), TBAF (0.5 equiv., 0.1 mL, 1.0 mol/L in THF), room temperature, 12 h. b Yields refer to isolated yields.

随后, 探究了硫酚底物对反应体系的相容性(Table 3). 以α-(三氟甲基)苯乙烯衍生物2m为底物, 与不同取代的硫酚在最优条件下反应. 当苯硫酚上的取代基为OMe、OH、t-Bu、Me等给电子基团时, 能够有效增加苯环的电子密度, 增强反应的亲核性, 以67%~87%的产率顺利合成目标化合物(Table 3, 4a~4e). 其中, 该反应体系对邻位甲基取代、带有一定空间位阻的硫醇底物表现出良好的耐受性, 能以67%~71%的产率得到产物(Table 3, 4d~4e). 同时, 含弱吸电子基(F)的硫醇底物产率高达82% (Table 3, 4f), 而中等强度的吸电子基(COOMe)显著降低硫负离子的亲核性, 使得目标产物的产率仅为51% (Table 3, 4g). 相比之下, 强吸电子基(NO2)通过降低苯环的电子云密度, 导致反应无法进行(Table 3, 4h). 该反应体系同样适用于杂芳基硫醇底物, 噻吩硫醇能以70%的产率生成相应化合物(Table 3, 4i), 进一步拓展了该方法的底物适用范围.
表3 底物对各取代硫酚普适性考察a,b

Table 3 Investigation of the universality of substrates to each thiophenol

a Reaction conditions (unless otherwise specified): 1 (0.2 mmol, 1.0 equiv.), 2m (0.3 mmol, 1.5 equiv.), TBAF (0.5 equiv., 0.1 mL, 1.0 mol/L in THF), room temperature, 12 h. b Yields refer to isolated yields.

接下来进行了克级规模放大反应和衍生化实验以验证该反应的实用性(Scheme 2). 在最优条件下, 将模板底物进行了克级规模放大实验, 以88%的产率得到了1.4347 g目标产物3a, 与小规模的反应收率相当(Scheme 2A). 此外, 以3a为底物进行了后续衍生化, 发现使用2 equiv.的m-CPBA可将硫醚在8 h内高效地氧化为相应的砜, 以92%的产率得到658.4 mg衍生化砜产物5a (Scheme 2B).
图式2 克级规模合成和衍生化实验

Scheme 2 Gram-scale synthesis and derivatization experiment

最后, 初步研究了喹啉酮及喹啉衍生物3n~3q对乳腺癌细胞和肝癌细胞的抗肿瘤活性, 发现将亚甲基替换成硫原子后, 这些分子对两种癌细胞没有表现出明显的抑制作用.
为了深入了解该反应可能的机理过程, 进行了系列探究实验(Scheme 3). 首先, 进行自由基抑制实验: 在最优条件下加入自由基抑制剂1,1-二苯乙烯(DPE)或2,6-二叔丁基对甲酚(BHT), 反应均可顺利进行, 能以92%或94%的高产率生成目标产物, 说明该反应不经历自由基过程(Scheme 3A), 反应更倾向于通过离子型途径进行. 为了验证质子来源, 使用氘代的对甲基硫酚(d-1a)代替对甲基硫酚(1a), 做了如下氘代实验(Scheme 3B). d-1a的重氢原子加成到烯烃上与三氟甲基相连的碳原子处, 生成氘代产物d-3a, 证实了质子来自硫酚的巯基部分而非其他位置的氢或溶剂.
图式3 自由基抑制实验和氘标记研究

Scheme 3 Radical inhibition experiment and deuterium-labeling study

基于实验结果及相关文献报道[17,19], 提出了无需额外添加溶剂条件下TBAF促进的α-(三氟甲基)苯乙烯与硫酚的氢硫醇化反应的可能机理(Scheme 4). 首先, TBAF (1.0 mol/L in THF)中的氟离子(F–)作为碱, 夺取苯硫酚(1a)的质子, 生成亲核性更强的硫醇负离子(A), 并伴随HF的生成. 随后, 硫醇负离子(A)对α-(三氟甲基)烯烃(2)进行区域选择性地亲核进攻, 由于CF3强吸电子效应产生的活化作用, 生成由CF3稳定的碳负离子中间体B. 最后中间体B发生质子化, 生成最终产物3, 完成反应.
图式4 可能的反应机理

Scheme 4 Plausible reaction mechanism

2 结论

本文报道了一种在无需额外添加溶剂条件下, 以四丁基氟化铵(TBAF)促进的α-(三氟甲基)苯乙烯与硫酚的氢硫醇化反应. 该方法操作简单、条件温和, 并显示出优异的官能团耐受性和化学选择性. 此外, 该方法原子经济性高, 目标产物的收率最高可达95%, 为合成β-三氟甲基硫醚类化合物提供了一种简洁、高效的途径.

3 实验部分

3.1 仪器与试剂

1H NMR、13C NMR和19F NMR图谱由Bruker- AVANCE NEO 400型光谱仪记录. NMR产率是通过19F NMR确定的, 使用氟化苯作为内标. 高分辨质谱在中国科学院上海有机化学研究所质谱分析实验室的JEOL- AccuTOF-GCv4G-GCT MS和Waters Premier GC-TOF MS上记录, 熔点在SGW X-4熔点仪上测定. 除非另有说明, 所有试剂均按商业来源提供的原样使用, 或按文献中描述的方法进行制备.

3.2 实验方法

3.2.1 α-(三氟甲基)苯乙烯(2)的合成

方法A[16]: 在配备磁力搅拌子的25.0 mL封管中, 依次投入芳基硼酸(3 mmol, 1.0 equiv.)、双(三苯基膦)二氯化钯(0.09 mmol, 3.0 mol%). 用氩气对体系进行三次置换后, 充氩气状态下依次加入碳酸钾水溶液(12 mmol, 4.0 equiv.)、四氢呋喃(9.0 mL)作为反应溶剂以及2-溴- 3,3,3-三氟丙烯(4.5 mmol, 1.5 equiv.), 密封反应体系后置于60 ℃油浴中, 加热搅拌反应12 h. 反应完毕, 冷却至室温, 以乙酸乙酯萃取有机相, 并用饱和氯化钠溶液洗涤, 合并有机层后用无水硫酸钠干燥, 减压浓缩得到粗品, 经硅胶柱层析分离纯化得到纯品.
方法B[16]: 在配备磁力搅拌子的25.0 mL封管中, 依次投入芳基溴化物(1.0 mmol, 1.0 equiv.)、X-Phos (0.08 mmol, 8 mol%)、碳酸钾(3.0 mmol, 3.0 equiv.)、醋酸钯(0.04 mmo1, 4 mol%). 抽真空后用氩气回填3次, 充氩气状态下依次加入乙腈(3.0 mL)、去离子水(1.5 mL)、1-(三氟甲基)乙烯硼酸己醇酯(1.5 mmol, 1.5 equiv.), 密封反应体系后于80 ℃油浴中加热搅拌反应48 h. 混合物冷却至室温, 用乙酸乙酯萃取有机相, 并用饱和氯化钠溶液洗涤, 合并有机层后用无水硫酸钠干燥, 减压浓缩得到粗产品, 经硅胶柱层析分离纯化得到纯品.

3.2.2 β-三氟甲基硫醚(3/4)的合成

向装有磁力搅拌子的25.0 mL封管中依次加入苯硫酚1 (0.2 mmol, 1.0 equiv.)和α-(三氟甲基)苯乙烯2 (0.3 mmol, 1.5 equiv.). 进行三次氩气抽换操作后, 充氩气状态下向该体系中加入TBAF (0.1 mmol, 0.5 equiv., 1.0 mol/L in THF), 将封管密封后, 置于室温下搅拌反应12 h. 反应结束后, 以氟化苯作为内标物, 通过19F NMR测定粗产率. 通过减压浓缩得到粗品, 以石油醚/乙酸乙酯为洗脱剂, 经硅胶柱层析分离纯化得到目标产物3和4.
克级反应: 向装有磁力搅拌子的25.0 mL封管中依次加入苯硫酚1a (5.0 mmol, 1.0 equiv.)和4-甲氧基-α- (三氟甲基)苯乙烯(2a) (7.5 mmol, 1.5 equiv.). 进行三次氩气抽换操作后, 向该体系中加入TBAF (2.5 mmol, 0.5 equiv., 1.0 mol/L in THF), 将封管密封后, 置于室温下搅拌反应12 h. 反应结束后, 通过减压浓缩得到粗品, 以石油醚/乙酸乙酯为洗脱剂, 经硅胶柱层析分离纯化得到目标产物3a (1.4347 g), 产率为88%.

3.3 化合物表征数据

3,3,3-三氟-2-(4-甲氧基苯基)丙基-对甲基苯基硫醚(3a): 白色固体, 45.7 mg, 70% yield [洗脱液: V(petro- leum ether, PE)∶ V(ethyl acetate, EA)=400∶1]. m.p. 28.8~30.7 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.21 (q, J=8.0 Hz, 4H), 7.13 (d, J=7.6 Hz, 2H), 6.92 (d, J=8.8 Hz, 2H), 3.83 (s, 3H), 3.56 (dd, J=13.2, 3.6 Hz, 1H), 3.46~3.36 (m, 1H), 3.24 (t, J=12.2 Hz, 1H), 2.35 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 159.7, 137.1, 131.0, 130.8, 130.2, 129.9, 126.2 (q, J=282.1 Hz), 125.1, 114.0, 55.1, 48.9 (q, J=26.4 Hz), 34.2, 21.0; 19F NMR (376 MHz, CDCl3) δ: –69.54 (d, J=8.9 Hz, 3F); HRMS (ESI) calcd for C17H17OF3SNa [M+Na]+ 349.0850, found 349.0857.
(2-(4-(苄氧基)苯基)-3,3,3-三氟丙基)(对甲基苯基)硫醚(3b): 棕色固体, 49.9 mg, 62% yield [洗脱液: V(PE)∶ V(EA)=400∶1]. m.p. 93.1~95.3 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.46~7.33 (m, 5H), 7.19 (q, J=8.0 Hz, 4H), 7.11 (d, J=8.0 Hz, 2H), 6.97 (d, J=8.8 Hz, 2H), 5.06 (s, 2H), 3.54 (dd, J=13.2, 3.2 Hz, 1H), 3.44~3.33 (m, 1H), 3.21 (t, J=12.0 Hz, 1H), 2.34 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 158.9, 137.2, 136.7, 131.1, 130.8, 130.3, 129.9, 128.6, 128.1, 127.5, 126.3 (q, J=282.3 Hz), 125.4, 114.9, 70.0, 48.9 (q, J=25.7 Hz), 34.2, 21.0; 19F NMR (376 MHz, CDCl3) δ: –69.54 (d, J=9.0 Hz, 3F); HRMS (ESI) calcd for C23H22OF3S [M+H]+ 403.1343, found 403.1337.
5-(1,1,1-三氟-3-(对甲基苯硫)丙基-2-基)苯并[d][1,3]二氧烯(3c): 无色液体, 59.2 mg, 87% yield [洗脱液: V(PE)∶V(EA)=400∶1]. 1H NMR (400 MHz, CDCl3) δ: 7.24 (d, J=8.0 Hz, 2H), 7.13 (d, J=8.0 Hz, 2H), 6.81 (d, J=7.6 Hz, 1H), 6.73 (t, J=8.0 Hz, 2H), 5.98 (d, J=1.6 Hz, 2H), 3.54 (dd, J=13.2, 3.6 Hz, 1H), 3.42~3.32 (m, 1H), 3.20 (t, J=12.0 Hz, 1H), 2.35 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 147.9, 147.8, 137.2, 131.1, 130.7, 129.9, 126.7, 126.0 (q, J=282.2 Hz), 123.1, 108.9, 108.3, 101.3, 49.4 (q, J=26.6 Hz), 34.2, 21.0; 19F NMR (376 MHz, CDCl3) δ: –69.46 (d, J=9.0 Hz, 3F); HRMS (ESI) calcd for C17H15O2F3SK [M+K]+ 379.0382, found 379.0387.
(2-(4-叔丁基苯基)-3,3,3-三氟丙基)(对甲基苯基)硫醚(3d): 白色固体, 45.1 mg, 64% yield (洗脱液: PE). m.p. 46.5~49.1 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.41 (d, J=6.6 Hz, 2H), 7.24 (t, J=8.8 Hz, 4H), 7.13 (d, J=8.0 Hz, 2H), 3.59 (dd, J=13.2, 2.8 Hz, 1H), 3.51~3.45 (m, 1H), 3.31 (t, J=12.0 Hz, 1H), 2.36 (s, 3H), 1.38 (s, 9H); 13C NMR (101 MHz, CDCl3) δ: 151.3, 137.0, 131.1, 131.0, 130.1 (d, J=1.4 Hz), 129.8, 128.7, 126.2 (q, J=281.9 Hz), 125.5, 49.5 (q, J=26.3 Hz), 34.5, 34.2 (d, J=2.2 Hz), 31.3, 21.0; 19F NMR (376 MHz, CDCl3) δ: –69.10 (d, J=9.4 Hz, 3F); HRMS (ESI) calcd for C20H24F3S [M+ H]+ 353.1551, found 353.1545.
2-(3,4-二氯苯基)-3,3,3-三氟丙基(对甲基苯基)硫醚(3e): 无色液体, 45.6 mg, 64% yield (洗脱液: PE). 1H NMR (400 MHz, CDCl3) δ: 7.43 (d, J=8.4 Hz, 1H), 7.31 (s, 1H), 7.20 (d, J=7.2 Hz, 2H), 7.13~7.07 (m, 3H), 3.56 (dd, J=13.6, 2.4 Hz, 1H), 3.46~3.36 (m, 1H), 3.19 (t, J=12.8 Hz, 1H), 2.36 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 137.7, 133.2, 132.9, 132.8, 131.5, 131.1, 130.5, 130.0, 129.9, 128.5, 125.5 (q, J=282.2 Hz), 49.3 (q, J=26.6 Hz), 33.8, 21.0; 19F NMR (376 MHz, CDCl3) δ: –69.22 (d, J=8.6 Hz, 3F); HRMS (ESI) calcd for C16H13F3SCl2K [M+K]+ 402.9704, found 402.9698.
N,N-二苯基-4-(1,1,1-三氟-3-(对甲基苯硫)丙基-2-基)苯胺(3f): 黄色液体, 84.4 mg, 91% yield [洗脱液: V(PE)∶V(EA)=20∶1]. 1H NMR (400 MHz, CDCl3) δ: 7.32~7.28 (m, 5H), 7.20~7.05 (m, 13H), 3.57 (dd, J=13.2, 3.6 Hz, 1H), 3.47~3.37 (m, 1H), 3.26 (t, J=12.0 Hz, 1H), 2.37 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 147.9, 147.4, 137.1, 131.03, 131.00, 129.9, 129.8, 129.3, 126.4, 126.2 (q, J=281.9 Hz), 124.8, 123.2, 122.6, 49.4 (q, J=26.3 Hz), 34.2, 21.0; 19F NMR (376 MHz, CDCl3) δ: –69.16 (d, J=8.6 Hz, 3F); HRMS (ESI) calcd for C28H25NF3S [M+H]+ 464.1660, found 464.1662.
4-(4-(1,1,1-三氟-3-(对甲基苯硫)丙基-2-基)苯基)吗啉(3g): 棕色固体, 54.9 mg, 72% yield [洗脱液: V(PE)∶V(EA)=20∶1]. m.p. 44.7~47.3 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.22 (d, J=7.6 Hz, 2H), 7.13 (dd, J=18.0, 8.0 Hz, 4H), 6.90 (d, J=8.4 Hz, 2H), 3.87 (t, J=4.2 Hz, 4H), 3.53 (dd, J=12.8, 2.8 Hz, 1H), 3.42~3.31 (m, 1H), 3.26~3.18 (m, 5H), 2.34 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 151.0, 137.0, 131.0, 130.9, 129.91, 129.86, 126.2 (q, J=282.2 Hz), 124.0, 115.2, 66.8, 48.8 (q, J=26.6 Hz), 48.7, 34.06 (d, J=1.3 Hz), 21.0; 19F NMR (376 MHz, CDCl3) δ: –69.50 (d, J=9.0 Hz, 3F); HRMS (ESI) calcd for C20H23NOF3S ([M+H]+): 382.1452, found 382.1454.
(2-([1'-联苯]-4-基)-3,3,3-三氟丙基)(对甲基苯基)硫醚(3h): 白色固体, 68.5 mg, 92% yield (洗脱液: PE). m.p. 75.1~76.9 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.63~7.59 (m, 4H), 7.47 (t, J=6.6 Hz, 2H), 7.40~7.33 (m, 3H), 7.25 (d, J=6.4 Hz, 2H), 7.13 (d, J=6.4 Hz, 2H), 3.62 (dd, J=13.2, 3.2 Hz, 1H), 3.57~3.47 (m, 1H), 3.32(t, J=8.0 Hz, 1H), 2.35 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 141.4, 140.4, 137.2, 132.2, 131.2, 130.7, 129.9, 129.6, 128.8, 127.5, 127.3, 127.1,126.1 (q, J=282.3 Hz), 49.5 (q, J=26.5 Hz), 34.1, 21.0; 19F NMR (376 MHz, CDCl3) δ: –69.04 (d, J=8.6 Hz, 3F). 表征数据与文献报道一致[20].
4-(1,1,1-三氟-3-(对甲基苯硫)丙基-2-基)苯基三甲基硅烷(3i): 白色固体, 37.6 mg, 51% yield [洗脱液: V(PE)∶V(EA)=120∶1]. m.p. 38.4~41.9 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.55 (d, J=7.2 Hz, 2H), 7.26 (t, J=8.6 Hz, 4H), 7.13 (d, J=8.0 Hz, 2H), 3.59 (dd, J=13.6, 2.8 Hz, 1H), 3.52~3.42 (m, 1H), 3.31 (t, J=12.0 Hz, 1H), 2.36 (s, 3H), 0.32 (s, 9H); 13C NMR (101 MHz, CDCl3) δ: 140.9, 137.2, 133.6, 131.2, 130.8, 129.9, 128.4, 126.1 (q, J=282.0 Hz), 49.8 (q, J=26.3 Hz), 34.1, 21.0, 1.2; 19F NMR (376 MHz, CDCl3) δ: –68.97 (d, J=9.4 Hz, 3F); HRMS (ESI) calcd for C19H24F3SSi [M+H]+ 369.1320, found 369.1311.
4-(1,1,1-三氟-3-(对甲基苯硫)丙基-2-基)苯甲酸(3j): 白色固体, 40.8 mg, 60% yield [洗脱液: V(PE)∶V(EA)=5∶1]. m.p. 112.1~116.4 ℃; 1H NMR (400 MHz, CDCl3) δ: 8.13 (d, J=8.0 Hz, 2H), 7.37 (d, J=8.0 Hz, 2H), 7.21 (d, J=8.0 Hz, 2H), 7.12 (d, J=8.0 Hz, 2H), 3.61 (dd, J=13.2, 3.2 Hz, 1H), 3.56~3.48 (m, 1H), 3.27 (t, J=12.4 Hz, 1H), 2.35 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 171.9, 139.2, 137.6, 131.4, 130.5, 130.1, 130.0, 129.53, 129.46, 125.7 (q, J=282.2 Hz), 49.8 (q, J=27.1 Hz), 33.9, 21.0; 19F NMR (376 MHz, CDCl3) δ: –68.85 (d, J=8.3 Hz, 3F); HRMS (ESI) calcd for C17H16O2F3S [M+H]+ 341.0823, found 341.0819.
4-(1,1,1-三氟-3-(对甲基苯硫)丙基)苯甲醛(3k): 白色固体, 36.3 mg, 56% yield [洗脱液: V(PE)∶V(EA)=30∶1]. m.p. 69.2~72.6 ℃; 1H NMR (400 MHz, CDCl3) δ: 10.03 (s, 1H), 7.88 (d, J=6.5 Hz, 2H), 7.42 (d, J=8.0 Hz, 2H), 7.19 (d, J=6.8 Hz, 2H), 7.11 (d, J=8.0 Hz, 2H), 3.59 (dd, J=12.4, 2.4 Hz, 1H), 3.55~3.47 (m, 1H), 3.25 (t, J=12.0 Hz, 1H), 2.33 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 191.6, 139.8, 137.6, 136.4, 131.4, 130.01, 129.96, 129.87, 125.6 (q, J=282.0 Hz), 49.8 (q, J=26.7 Hz), 33.8, 21.0; 19F NMR (376 MHz, CDCl3) δ: –68.81 (d, J=8.6 Hz, 3F); HRMS (ESI) calcd for C17H16OF3S [M+H]+ 325.0874, found 325.0867.
1-(4-(1,1,1-三氟-3-(对甲基苯硫)丙基-2-基)苯基)乙酮(3l): 白色固体, 59.6 mg, 88% yield [洗脱液: V(PE)∶V(EA)=100∶1]. m.p. 60~61.4 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.95 (d, J=8.4 Hz, 2H), 7.34 (d, J=8.0 Hz, 2H), 7.19 (d, J=8.0 Hz, 2H), 7.10 (d, J=7.6 Hz, 2H), 3.58 (dd, J=13.2, 3.6 Hz, 1H), 3.52~3.44 (m, 1H), 3.25 (t, J=12.2 Hz, 1H), 2.62 (s, 3H), 2.33 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 197.5, 138.4, 137.6, 137.2, 131.4, 130.2, 130.0, 129.5, 128.6, 125.7 (q, J=282.3 Hz), 49.7 (q, J=26.7 Hz), 33.9, 26.6, 21.1; 19F NMR (376 MHz, CDCl3) δ: –68.95 (d, J=8.6 Hz, 3F); HRMS (ESI) calcd for C18H18- OF3S [M+H]+ 339.1030, found 339.1031.
吡咯烷-1-(4-(1,1,1-三氟-3-(对甲基苯硫)丙基-2-基)苯基)甲酮(3m): 无色液体, 63.7 mg, 81% yield [洗脱液: V(PE)∶V(EA)=20∶1]. 1H NMR (400 MHz,CDCl3) δ: 7.52 (d, J=8.4 Hz, 2H), 7.28 (s, 2H), 7.19 (d, J=8.0 Hz, 2H), 7.10 (d, J=7.6 Hz, 2H), 3.57~3.39 (m, 6H), 3.22 (t, J=12.0 Hz, 1H), 2.33 (s, 3H), 1.92 (s, 4H); 13C NMR (101 MHz, CDCl3) δ: 169.0, 137.4, 137.3, 134.9, 131.2, 130.4, 130.0, 129.1, 127.5, 125.9 (q, J=281.9 Hz), 49.6 (q, J=26.6 Hz), 46.2, 33.9, 25.4 (d, J=195.6 Hz), 21.0; 19F NMR (376 MHz, CDCl3) δ: –69.05 (d, J=8.6 Hz, 3F); HRMS (ESI) calcd for C21H23NOF3S [M+H]+ 394.1452, found 394.1456.
1-甲基-3-(1,1,1-三氟-3-(对甲基苯硫)丙基-2-基)喹啉-2(1H)-酮(3n): 白色固体, 71.7 mg, 95% yield [洗脱液: V(PE)∶V(EA)=20∶1]. m.p. 78.4~81.5 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.73 (s, 1H), 7.63~7.55 (m, 2H), 7.36 (d, J=8.8 Hz, 1H), 7.30~7.26 (m, 3H), 7.05 (d, J=6.8 Hz, 2H), 4.62~4.51 (m, 1H), 3.78 (s, 3H), 3.56 (dd, J=13.6, 2.4 Hz, 1H), 3.45 (t, J=12.2 Hz, 1H), 2.27 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 161.5, 139.4, 137.8, 137.2, 131.5, 130.9, 129.6, 128.9, 126.0 (q, J=282.3 Hz), 125.3, 122.2, 119.6, 113.8, 42.5 (q, J=28.4, Hz), 34.0, 30.0, 20.8; 19F NMR (376 MHz, CDCl3) δ: –68.86 (s, 3F); HRMS (ESI) calcd for C20H19NOF3S [M+H]+ 378.1139, found 378.1142.
3-(1,1,1-三氟-3-(对甲基苯硫)丙基-2-基)喹啉- 2(1H)-酮(3o): 白色固体, 40.0 mg, 55% yield [洗脱液: V(PE)∶V(EA)=18∶1]. m.p. 49.1~52.8 ℃; 1H NMR (400 MHz, CDCl3) δ: 12.52 (s, 1H), 7.79 (s, 1H), 7.53 (d, J=6.8 Hz, 2H), 7.39 (d, J=8.0 Hz, 1H), 7.29~7.23 (m, 3H), 6.99 (d, J=7.6 Hz, 2H), 4.54~4.44 (m, 1H), 3.57~3.53 (m, 1H), 3.41 (t, J=12.0 Hz, 1H), 2.22 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 161.7, 139.6, 138.0, 137.5, 131.9, 131.0, 130.9, 129.8, 128.0, 126.1 (q, J=282.0 Hz), 122.8, 119.4, 115.9, 34.3, 29.7, 21.0; 19F NMR (376 MHz, CDCl3) δ: –68.90 (d, J=8.6 Hz, 3F); HRMS (ESI) calcd for C19H17NOF3S [M+H]+ 364.09775, found 364.09723.
8-(1,1,1-三氟-3-(对甲基苯硫)丙基-2-基)喹啉(3p): 无色液体, 54.2 mg, 78% yield [洗脱液: V(PE)∶V(EA)=50∶1]. 1H NMR (400 MHz, CDCl3) δ: 8.94~8.93 (m, 1H), 8.16 (d, J=8.0 Hz, 1H), 7.82 (d, J=8.0 Hz, 2H), 7.58 (t, J=8.0 Hz, 1H), 7.43 (q, J=4.0 Hz, 1H), 7.17 (d, J=7.6 Hz, 2H), 7.05 (d, J=8.0 Hz, 2H), 5.73 (s, 1H), 3.73 (dd, J=13.2, 4.0 Hz, 1H), 3.52 (t, J=12.0 Hz, 1H), 2.32 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 149.7, 146.9, 136.9, 136.3, 132.6, 131.3, 129.6, 128.3, 128.2, 126.7 (q, J=281.9 Hz), 126.1, 121.3, 40.8 (q, J=26.0 Hz), 35.3, 21.0; 19F NMR (376 MHz, CDCl3) δ: –68.26 (d, J=9.4 Hz, 3F); HRMS (ESI) calcd for C19H17NF3S [M+H]+ 348.1034, found 348.1038.
3-(1,1,1-三氟-3-(甲基苯硫)丙基-2-基)喹啉(3q): 白色固体, 44.1 mg, 63% yield [洗脱液: V(PE)∶V(EA)=80∶1]. m.p. 49.1~52.8 ℃; 1H NMR (400 MHz, CDCl3) δ: 8.74 (s, 1H), 8.13 (d, J=8.4 Hz, 1H), 8.01 (s, 1H), 7.79~7.72 (m, 2H), 7.57 (t, J=7.4 Hz, 2H), 7.15 (d, J=8.0 Hz, 2H), 7.02 (d, J=7.6 Hz, 2H), 3.71~3.62 (m, 2H), 3.56 (t, J=13.4 Hz, 1H), 2.23 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 151.2, 148.0, 137.8, 136.3, 131.7, 130.2, 130.1, 130.0, 129.3, 128.7 (q, J=282.2 Hz), 128.0, 127.7, 127.2, 126.4, 48.1 (q, J=27.2 Hz), 34.1, 21.1; 19F NMR (376 MHz, CDCl3) δ: –69.01 (d, J=8.6 Hz, 3F); HRMS (ESI) calcd for C19H17NF3S [M+H]+ 348.1026, found 348.1022.
3-(1,1,1-三氟-3-(对甲苯硫基)丙-2-基)吡啶(3r): 无色液体, 36.3 mg, 61% yield [洗脱液: V(PE)∶V(EA)=25∶1]. 1H NMR (400 MHz, CDCl3) δ: 8.58 (s, 1H), 8.44 (s, 1H), 7.56 (d, J=8.0 Hz, 1H), 7.32~7.25 (m, 1H), 7.18~7.07 (m, 4H), 3.58 (dd, J=13.2, 3.6 Hz, 1H), 3.47~3.37 (m, 1H), 3.18 (t, J=12.8 Hz, 1H), 2.30 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 150.7, 149.7, 137.6, 136.0, 131.5, 130.0, 129.8, 129.1, 125.7 (q, J=282.0 Hz), 123.5, 47.5 (q, J=27.1 Hz), 33.7 (d, J=1.3 Hz), 20.9; 19F NMR (376 MHz, CDCl3) δ: –69.14 (d, J=9.0 Hz, 3F); HRMS (ESI) calcd for C15H15NF3S [M+H]+ 298.0872, found 298.0867.
N-(5-(1,1,1-三氟-3-(对甲苯硫基)丙-2-基)吡啶-2-基)乙酰胺(3s): 无色液体, 50.3 mg, 71% yield [洗脱液: V(PE)∶V(EA)=8∶1]. 1H NMR (400 MHz, CDCl3) δ: 9.47 (s, 1H), 8.26 (d, J=8.8 Hz, 1H), 8.10 (s, 1H), 7.59 (d, J=8.8 Hz, 1H), 7.14~7.07 (m, 4H), 3.57 (dd, J=13.6, 3.6 Hz, 1H), 3.45~3.39 (m, 1H), 3.16 (t, J=12.6 Hz, 1H), 2.31 (s, 3H), 2.19 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 169.0, 151.9, 148.2, 138.7, 137.6, 131.3, 130.0, 129.9, 125.7 (q, J=282.0 Hz), 124.7, 114.2, 47.0 (q, J=27.1 Hz), 33.5, 24.4, 20.9; 19F NMR (376 MHz, CDCl3) δ: –69.41 (d, J=9.0 Hz, 3F); HRMS (ESI) calcd for C17H17O- N2F3NaS [M+Na]+ 377.0906, found 377.0901.
5-(1,1,1-三氟-3-(对甲苯硫基)丙-2-基)嘧啶(3t): 无色液体, 33.4 mg, 56% yield [洗脱液: V(PE)∶V(EA)=25∶1]. 1H NMR (400 MHz, CDCl3) δ: 9.18 (s, 1H), 8.57 (s, 2H), 7.15~7.08 (m, 4H), 3.61 (dd, J=14.4, 4.0 Hz, 1H), 3.46~3.52 (m, 1H), 3.17 (t, J=12.8 Hz, 1H), 2.31 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 158.6, 157.3, 138.1, 131.6, 130.2, 129.1, 127.3, 125.3 (q, J=282.2 Hz), 46.1 (q, J=27.6 Hz), 33.1 (d, J=2.3 Hz), 21.0; 19F NMR (376 MHz, CDCl3) δ: –69.09 (d, J=9.0 Hz, 3F); HRMS (ESI) calcd for C14H14N2F3S [M+H]+ 299.0824, found 299.0821.
5-(1,1,1-三氟-3-(对甲苯硫基)丙-2-基)噻唑-4-甲酸乙酯(3u): 浅黄色固体, 38.2 mg, 51% yield [洗脱液: V(PE)∶V(EA)=30∶1]. m.p. 86.3~88.4 ℃; 1H NMR (400 MHz, CDCl3) δ: 8.76 (s, 1H), 7.13~7.02 (m, 4H), 5.37~5.27 (m, 1H), 4.37~4.22 (m, 2H), 3.58 (dd, J=14.0, 3.6 Hz, 1H), 3.05~2.98 (m, 1H), 2.25 (s, 3H), 1.30 (t, J=7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ: 161.5, 152.3, 145.8, 139.5, 137.6, 131.5, 129.7, 129.6, 124.7 (q, J=282.5 Hz), 61.5, 42.0 (q, J=28.5 Hz), 36.3, 20.8, 13.8; 19F NMR (376 MHz, CDCl3) δ: –69.87 (d, J=8.3 Hz); HRMS (ESI) calcd for C16H16O2NF3NaS2 [M+Na]+ 398.0467, found 398.0461.
2-(1,1,1-三氟-3-(对甲基苯硫)丙基-2-基)苯并呋喃(3v): 白色固体, 36.3 mg, 54% yield [洗脱液: V(PE)∶V(EA)=10∶1]. m.p. 40.1~42.4 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.58 (d, J=7.6 Hz, 1H), 7.48 (d, J=8.4 Hz, 1H), 7.33 (t, J=8.0 Hz, 1H), 7.29~7.25 (m, 3H), 7.08 (d, J=8.0 Hz, 2H), 6.73 (s, 1H), 3.81~3.70 (m, 1H), 3.56~3.44 (m, 2H), 2.31 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 155.0, 149.2 (d, J=2.5 Hz), 137.6, 131.6, 130.1, 129.9, 127.8, 124.8 (q, J=282.6 Hz), 124.6, 122.9, 121.0, 111.4, 107.7, 45.0 (q, J=28.5 Hz), 32.3, 21.0; 19F NMR (376 MHz,CDCl3) δ: –69.07 (d, J=8.6 Hz, 3F); HRMS (ESI) calcd for C18H16OF3S [M+H]+ 337.0874, found 337.0870.
6-(1,1,1-三氟-3-(对甲基苯硫)丙基-2-基)香豆素(3w): 棕色固体, 48.1 mg, 66% yield [洗脱液: V(PE)∶V(EA)=10∶1]. m.p. 70.7~73.8 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.65 (d, J=10.0 Hz, 1H), 7.38 (d, J=8.4 Hz, 1H), 7.30 (d, J=8.8 Hz, 2H), 7.15 (d, J=7.6 Hz, 2H), 7.07 (d, J=7.6 Hz, 2H), 6.44 (d, J=9.6 Hz, 1H), 3.60~3.45 (m, 2H), 3.24 (t, J=12.4 Hz, 1H), 2.30 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 160.3, 153.8, 143.0, 137.5, 132.5, 131.2, 130.0, 129.9, 129.3, 128.5, 125.7 (q, J=281.9 Hz), 118.8, 117.1, 117.0, 49.2 (q, J=27.0 Hz), 33.8, 20.9; 19F NMR (376 MHz, CDCl3) δ: –69.32 (d, J=8.6 Hz, 3F); HRMS (ESI) calcd for C19H16O2F3S [M+H]+ 365.0823, found 365.0826.
3-(1,1,1-三氟-3-(对甲基苯硫)丙基-2-基)苯并噻吩(3x): 白色固体, 57.1 mg, 81% yield [洗脱液: V(PE)∶V(EA)=50∶1]. m.p. 46.3~48.4 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.80 (d, J=8.0 Hz, 1H), 7.73 (d, J=8.0 Hz, 1H), 7.38~7.31 (m, 2H), 7.26~7.23 (m, 3H), 7.09 (d, J=8.0 Hz, 2H), 3.82~3.72 (m, 1H), 3.58 (dd, J=13.6, 3.2 Hz, 1H), 3.25 (t, J=12.0 Hz, 1H), 2.31 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 139.7, 139.1, 137.6, 135.7, 131.5, 130.2, 130.0, 125.4, 125.3 (q, J=282.3 Hz), 124.7, 124.5, 123.7, 122.2, 46.2 (q, J=28.1 Hz), 35.2, 21.0; 19F NMR (376 MHz,CDCl3) δ: –69.69 (d, J=9.0 Hz, 3F); HRMS (ESI) calcd for C18H16F3S2 [M+H]+ 353.0646, found 353.0639.
5-(1,1,1-三氟-3-(对甲基苯硫)丙基-2-基)苯并[d][1,3]二氧烯(4a): 白色固体, 62.0 mg, 87% yield [洗脱液: V(PE)∶V(EA)=400∶1]. m.p. 72.2~75.7 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.22 (t, J=8.0 Hz, 1H), 6.90 (d, J=7.2 Hz, 1H), 6.34 (s, 1H), 6.80~6.71 (m, 4H), 5.98 (s, 2H), 3.80 (s, 3H), 3.59 (dd, J=13.2, 3.2 Hz, 1H), 3.47~3.37 (m, 1H), 3.23 (t, J=12.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ: 159.9, 148.0, 147.8, 135.9, 130.0, 126.6, 126.0 (q, J=282.0 Hz), 123.1, 122.1, 115.3, 112.6, 108.9, 108.3, 101.3, 55.2, 49.5 (q, J=26.7 Hz), 33.4 (d, J=1.6 Hz); 19F NMR (376 MHz, CDCl3) δ: –69.47 (d, J=9.0 Hz, 3F); HRMS (ESI) calcd for C17H16O3F3S [M+H]+ 357.0766, found 357.0763.
4-((2-(苯并[d][1,3]二氧烯-5-基)-3,3,3-三氟丙基)硫)苯酚(4b): 无色液体, 50.7 mg, 74% yield [洗脱液: V(PE)∶V(EA)=30∶1]. 1H NMR (400 MHz, CDCl3) δ: 7.23 (d, J=8.4 Hz, 2H), 6.78 (t, J=9.0 Hz, 3H), 6.70 (d, J=8.4 Hz, 2H), 5.97 (s, 2H), 5.55 (s, 1H), 3.43 (dd, J=13.2, 3.2 Hz, 1H), 3.37~3.27 (m, 1H), 3.14 (t, J=12.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ: 155.5, 147.9, 147.7, 134.4, 126.7, 126.0 (q, J=282.0 Hz), 124.7, 123.2, 116.2, 108.9, 108.3, 101.3, 49.5 (q, J=26.5 Hz), 35.4 (d, J=1.3 Hz); 19F NMR (376 MHz, CDCl3) δ: –69.49 (d, J=9.0 Hz, 3F); HRMS (ESI) calcd for C16H12O3F3S [M–H]– 341.0465, found 341.0463.
5-(3-((4-叔丁基苯基)硫基)-1,1,1-三氟丙-2-基)苯并[d][1,3]二氧杂环戊烯(4c): 无色液体, 62.0 mg, 80% yield (洗脱液: PE). 1H NMR (400 MHz, CDCl3) δ: 7.30~7.19 (m, 4H), 6.76~6.68 (m, 4H), 5.91 (s, 2H), 3.52 (dd, J=14.0, 4.0 Hz, 1H), 3.43~3.33 (m, 1H), 3.19 (t, J=12.0 Hz, 1H), 1.29 (s, 9H); 13C NMR (101 MHz, CDCl3) δ: 150.3, 147.9, 147.8, 130.9, 130.5, 126.7, 126.1,126.1 (q, J=282.1 Hz), 123.1, 108.9, 108.3, 101.2, 49.6 (q, J=26.5 Hz), 34.5, 33.9, 31.2; 19F NMR (376 MHz, CDCl3) δ: –68.85 (d, J=9.0 Hz, 3F); HRMS (ESI) calcd for C20H21F3NaO2S [M+Na]+ 405.1107, found 405.1092.
5-(3-((2,6-二甲基苯基)硫基)-1,1,1-三氟丙-2-基)苯并[d][1,3]二氧杂环戊烯(4d): 无色液体, 47.5 mg, 67% yield (洗脱液: PE). 1H NMR (400 MHz, CDCl3) δ: 7.18~7.08 (m, 3H), 6.80~6.72 (m, 3H), 5.99 (s, 2H), 3.56~3.30 (m, 2H), 3.11 (t, J=12.0 Hz, 1H), 2.43 (s, 6H); 13C NMR (101 MHz, CDCl3) δ: 147.9, 147.8, 142.9, 132.4, 128.5, 128.2, 126.7, 126.0 (q, J=282.3 Hz), 123.1, 108.9, 108.3, 101.3, 49.9 (q, J=26.5 Hz), 33.5, 21.8; 19F NMR (376 MHz, CDCl3) δ: –69.79 (d, J=8.6 Hz, 3F); HRMS (EI-TOF) calcd for C18H17F3O2S [M]+ 354.0896, found 354.0880.
5-(1,1,1-三氟-3-(邻甲苯硫基)丙-2-基)苯并[d][1,3]二氧杂环戊烯(4e): 无色液体, 48.3 mg, 71% yield (洗脱液: PE). 1H NMR (400 MHz, CDCl3) δ: 7.26~7.25 (m, 1H), 7.15~7.08 (m, 3H), 6.76~6.66 (m, 3H), 5.92 (s, 2H), 3.50 (dd, J=10.0, 6.0 Hz, 1H), 3.43~3.32 (m, 1H), 3.19 (t, J=12.0 Hz, 1H), 2.27 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 147.9, 147.8, 138.7, 133.9, 130.4, 129.5, 126.7, 126.6, 126.5, 123.1,126.0 (q, J=280.4 Hz), 127.4, 124.6, 121.9,108.8, 108.3, 101.3, 49.4 (q, J=26.5 Hz), 49.5, 49.3, 49.0, 32.8, 20.3; 19F NMR (376 MHz, CDCl3) δ: –68.98 (d, J=8.6 Hz, 3F); HRMS (ESI) calcd for C17H14F3O2S [M–H]– 339.0667, found 339.0674.
5-(1,1,1-三氟-3-((4-氟苯基)硫基)丙-2-基)苯并[d][1,3]二氧杂环戊烯(4f): 无色液体, 56.5 mg, 82% yield (洗脱液: PE). 1H NMR (400 MHz, CDCl3) δ: 7.28~7.22 (m, 2H), 6.96 (t, J=8.0 Hz, 2H), 6.77~6.66 (m, 3H), 5.94 (s, 2H), 3.46 (dd, J=12.0, 4.0 Hz, 1H), 3.39~3.28 (m, 1H), 3.18 (t, J=12.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ: 163.4, 160.9, 147.9, 147.7, 133.5, 133.4, 129.6 (d, J=3.3 Hz), 126.4, 126.0 (q, J=282.8 Hz), 123.2, 116.3, 116.1, 108.8, 108.3, 101.3, 49.8 (q, J=26.6 Hz), 34.9; 19F NMR (376 MHz, CDCl3) δ: –69.14 (d, J=8.6 Hz, 3F), –113.59~–113.67 (m, 1F); HRMS (ESI) calcd for C16H11F4O2S [M–H]– 343.0421, found 343.0418.
4-((2-(苯并[d][1,3]二氧杂环戊烯-5-基)-3,3,3-三氟丙基)硫基)苯甲酸甲酯(4g): 无色液体, 38.4 mg, 50% yield [洗脱液: V(PE)∶V(EA)=35∶1]. 1H NMR (400 MHz, CDCl3) δ: 7.92 (d, J=8.4 Hz, 2H), 7.25 (d, J=8.4 Hz, 2H), 6.77~6.68 (m, 3H), 5.94 (s, 2H), 3.89 (s, 3H), 3.62 (dd, J=13.2, 3.6 Hz, 1H), 3.48~3.38 (m, 1H), 3.28 (t, J=12.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ: 166.5, 148.02, 147.97, 141.7, 130.1, 127.7, 127.5, 126.2, 125.9 (q, J=282.0 Hz), 123.0, 108.7, 108.4, 101.3, 52.0, 49.3 (q, J=27.0 Hz), 32.2 (d, J=1.2 Hz); 19F NMR (376 MHz, CDCl3) δ: –69.51 (d, J=8.6 Hz, 3F); HRMS (ESI) calcd for C18H16O4F3S [M+H]+ 385.0716, found 385.0710.
5-(1,1,1-三氟-3-(噻吩-2-基硫基)丙-2-基)苯并[d]- [1,3]二氧杂环戊烯(4h): 无色液体, 46.5 mg, 70% yield (洗脱液: PE). 1H NMR (400 MHz, CDCl3) δ: 7.39~7.38 (m, 1H), 7.08~7.07 (m, 1H), 6.99~6.97 (m, 1H), 6.84~6.75 (m, 3H), 5.95 (s, 2H), 3.43~3.36 (m, 2H), 3.13 (t, J=14.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ: 148.0, 147.9, 134.7, 132.5, 127.7, 126.4, 126.0 (q, J=282.0 Hz), 123.3, 109.0, 108.4, 101.3, 49.4 (q, J=26.7 Hz), 37.9; 19F NMR (376 MHz, CDCl3) δ: –69.40 (d, J=8.6 Hz, 3F); HRMS (ESI) calcd for C14H12F3O2S2 [M+H]+ 333.0225, found 333.0218.
1-甲氧基-4-(1,1,1-三氟-3-对甲苯磺酰基丙-2-基)苯(5a): 白色固体, 658.4 mg, 92% yield [洗脱液: V(PE)∶V(EA)=5∶1]. m.p. 96.4~98.1 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.45 (d, J=8.0 Hz, 2H), 7.14 (d, J=8.0 Hz, 2H), 7.02 (d, J=8.4 Hz, 2H), 7.71 (d, J=8.8 Hz, 2H), 3.94~3.84 (m, 1H), 3.76 (s, 3H), 3.71~3.66 (m, 2H), 2.37 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 159.8, 144.6, 136.0, 130.2, 129.6, 127.8, 125.4 (q, J=281.3 Hz), 122.8, 114.0, 55.4, 55.1, 45.5 (q, J=28.6 Hz), 21.4; 19F NMR (376 MHz, CDCl3) δ: –70.40 (d, J=9.0 Hz, 3F); HRMS (ESI) calcd for C17H17O3F3NaS [M+Na]+ 381.0743, found 357.0736.
辅助材料(Supporting Information) 化合物3a~3x和4a~4g、4i、5a的1H NMR、19F NMR和13C NMR谱图. 这些材料可以免费从本刊网站(http://sioc-journal.cn/)上下载.
(Cheng, F.)
[1]
(a) Shah, P.; Westwell, A. D. J. Enzyme Inhib. Med. Chem. 2007, 22, 527.

DOI

(b) Müller, K.; Faeh, C.; Diederich, F. Science 2007, 317, 1881.

DOI

(c) Kirk, K. L. Org. Process Res. Dev. 2008, 12, 305.

DOI

(d) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Chem. Soc. Rev. 2008, 37, 320.

DOI

(e) Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, C.; Sorochinsky, A. E.; Fustero, S.; Soloshonok, V. A.; Liu, H. Chem. Rev. 2014, 114, 2432.

DOI

(f) Alonso, C.; Martínez de Marigorta, E.; Rubiales, G.; Palacios, F. Chem. Rev. 2015, 115, 1847.

DOI

(g) Preshlock, S.; Tredwell, M.; Gouverneur, V. Chem. Rev. 2016, 116, 719.

DOI PMID

(h) Johnson, B. M.; Shu, Y.-Z.; Zhuo, X.; Humphreys, W. G. J. Med. Chem. 2020, 63, 6315.

DOI

[2]
(a) Koike, T.; Akita, M. Acc. Chem. Res. 2016, 49, 1937.

DOI

(b) Shen, H.; Liu, Z.; Zhang, P.; Tan, X.; Zhang, Z.; Li, C. J. Am. Chem. Soc. 2017, 139, 9843.

DOI

(c) Gao, X.; Xiao, Y.-L.; Wan, X.; Zhang, X. Angew. Chem., Int. Ed. 2018, 57, 3187.

DOI

(d) Kornfilt, D. J. P.; MacMillan, D. W. C. J. Am. Chem. Soc. 2019, 141, 6853.

DOI PMID

(e) Bhaskaran, R. P.; Babu, B. P. Adv. Synth. Catal. 2020, 362, 5219.

DOI

(f) Barata-Vallejo, S.; Postigo, A. Chem.-Eur. J. 2020, 26, 11065.

DOI

(g) Kisukuri, C. M.; Fernandes, V. A.; Delgado, J. A. C.; Häring, A. P.; Paixão, M. W.; Waldvogel, S. R. Chem. Rec. 2021, 21, 2502.

DOI

(h) Choi, G.; Lee, G. S.; Park, B.; Kim, D.; Hong, S. H. Angew. Chem., Int. Ed. 2021, 60, 5467.

DOI

(i) Xiao, H.; Zhang, Z.; Fang, Y.; Zhu, L.; Li, C. Chem. Soc. Rev. 2021, 50, 6308.

DOI

(j) Nair, P. P. R.; Philip, M.; Anilkumar, G. Catal. Sci. Technol. 2021, 11, 6317.

DOI

(k) Saranya, P. V.; Anilkumar, G.; Vaishak, T. B.; Soumya, P. K. Catal. Sci. Technol. 2021, 11, 4690.

DOI

(l) Guo, W.; Cheng, L.; Ma, G.; Tong, W.; Wu, F. Org. Lett. 2022, 24, 1796.

DOI

(m) Guo, P.; Tao, M.; Xu, W.-W.; Wang, A.-J.; Li, W.; Yao, Q.; Tong, J.; He, C.-Y. Org. Lett. 2022, 24, 2143.

DOI

(n) Guo, P.; Pu, G.; Wang, G.; Zeng, L.-Y.; Li, W.-P.; Li, X.; Zhou, P.-P.; He, C.-Y. Org. Lett. 2024, 26, 3097.

DOI

(o) Zhao, W.-W.; Zhang, Y.; Li, X.; Wang, L.; Liu, S.; Chen, J.; He, Y.; Xu, T. Angew. Chem., Int. Ed. 2024, 63, e202318887.

(p) Liu, L.-J.; Tian, M.-Y.; Lang, Z.-Y.; Wang, Y.-L.; He, C.-Y.; Chen, Y.-Z.; Han, W.-Y. Angew. Chem., Int. Ed. 2025, 64, e202501966.

(q) Tian, M.-Y.; Shao, Y.-C.; Zhao, W.-W.; Lang, Z.-Y.; Zhao, J.-F.; Lu, Y.-J.; He, C.-Y.; Chen, Y.-Z.; Han, W.-Y. Sci. China Chem. 2025, 68, 5754.

DOI

(r) Zhang, H.; Xiao, L.; Guo, H.; Pu, G.; Zhang, Y.; Liang, J.; Wang, P.; Yao, Q.; He, C.-Y. Org. Lett. 2025, 27, 13655.

DOI

[3]
(a) Jacob, C. Nat. Prod. Rep. 2006, 23, 851.

DOI

(b) Clayden, J.; MacLellan, P. Beilstein J. Org. Chem. 2011, 7, 582.

DOI

(c) Scott, K. A.; Njardarson, J. T. Top. Curr. Chem. 2018, 376, 5.

(d) Wang, N.; Saidhareddy, P.; Jiang, X. Nat. Prod. Rep. 2020, 37, 246.

DOI

(e) Hai, Y.; Wei, M.-Y.; Wang, C.-Y.; Gu, Y.-C.; Shao, C.-L. Mar. Life Sci. Technol. 2021, 3, 488.

DOI

(f) Yang, B.; Yang, Z.-D.; Ma, K.-Z.; Guo, W.-L.; Zhang, T.-H.; Zhao, T.-K. Phytochemistry 2023, 209, 113613.

DOI

(g) Chen, X.; Li, B. Curr. Opin. Chem. Biol. 2023, 76, 102377.

DOI

[4]
Dakhama, A.; Gelfand, E. W.; Han, J.; Jia, Y.; Takeda, K.; Shiraishi, Y.; Okamoto, M. Am. J. Respir. Crit. Care Med. 2010, 182, 455.

DOI

[5]
Mor-Ochomogo, M.; Lohans, C. T. M. J. RSC Med. Chem. 2021, 12, 1623.

DOI

[6]
(a) Qin, F.; Wang, Q.; Zhang, C.; Fang, C.; Zhang, L.; Chen, H.; Zhang, M.; Cheng, F. Infect. Drug Resist. 2018, 11, 1893.

DOI

(b) Hacioglu, M.; Guzel, C. B.; Savage, P. B.; Tan, A. S. B. Med. Mycol. 2019, 57, 291.

DOI PMID

[7]
Vela, P.; Llama, E.; Santos, A.; Ochoa, B. Tetrahedron 2005, 61, 6580.

DOI

[8]
(a) Aruoma, O. I.; Halliwell, B.; Hoey, B. M.; Butler, J. Redox Rep. 2004, 9, 167.

DOI

(b) Gillis, E. P.; Eastman, K. J.; Hill, M. D.; Donnelly, D. J.; Meanwell, N. A. J. Med. Chem. 2015, 58, 8315.

DOI PMID

[9]
(a) Feng, M.; Tang, B.; Liang, S. H.; Jiang, X. Curr. Top. Med. Chem. 2016, 16, 1200.

DOI

(b) Johansson, S.; Read, J.; Oliver, S.; Steinberg, M.; Li, Y.; Lisbon, E.; Mathews, D.; Leese, P. T.; Martin, P. Clin. Pharmacokinet. 2014, 53, 837.

DOI PMID

[10]
(a) Robinson, D. J.; Davies, L.; McGuire, N.; Khouzam, M.; Brunner, P. Chem. Chem. Phys. 2000, 2, 1523.

DOI

(b) Dong, H. K.; Kim, A. L.; Lee, J. Org. Lett. 2018, 20, 764.

DOI PMID

(c) Kupwade, R. V.; Patil, S. B.; Ramesh, S.; Sharma, A.; Yadav, A.; Mehra, R.; Sharma, S.; Pandey, A.; Singh, R.; Gupta, P. J. Chem. Rev. 2019, 1, 99.

DOI

(d) Cheng, Z.; Liu, X.; Zhang, H.; Wang, L.; Zhang, Y.; Wang, Z.; Zeng, X. Org. Lett. 2019, 21, 8925.

DOI PMID

(e) Cetina-Mancilla, E.; Pérez, J. A.; González, D.; Rodríguez, P.; López, M. A.; Sánchez, R. Eur. Polym. J. 2023, 184, 111800.

DOI

(f) Wu, X.; Hou, G.; Zhang, J.; Li, Y.; Wang, Z.; Chen, L.; Yang, H. Org. Lett. 2024, 26, 5917.

DOI

(g) Xiang, M.; Zhang, T.; Li, W.; Ding, Y.; Chen, J.; Hu, C.; Yan, Z.; Xu, Z. J. Catal. 2025, 442, 115905.

DOI

[11]
(a) Feng, X.-T.; Ren, J.-X.; Gao, X.; Min, Q.-Q.; Zhang, X. Angew. Chem., Int. Ed. 2022, 61, e202210103.

(b) Gao, X.; Ren, X.; Deng, W.; Zhang, X. Chin. J. Chem. 2023, 41, 3521.

DOI

(c) Feng, X.-T.; Min, Q.-Q.; Zeng, X.; Zhao, H.-Y.; Zhang, X. ACS Catal. 2024, 14, 5879.

DOI

(d) Ren, J.-X.; Zhou, M.; Feng, X.-T.; Zhao, H.-Y.; Fu, X.-P.; Zhang, X. Chem. Sci. 2024 15, 10002.

DOI

(e) Qu, M.-X.; Zhang, J.; Zhao, H.-Y.; Zhang, X. Eur. J. Org. Chem. 2025, 28, 2500625.

(f) Deng, W.; Geng, S.; Zhao, H.-Y.; Zhang, X. ACS Catal. 2025, 15, 14627.

DOI

(g) Feng, X.-T.; Min, Q.-Q.; Zhang, S.-Y.; Zhao, H.-Y.; Zhang, X. Chem. Sci. 2025, 16, 16552.

DOI

[12]
Yang, Y.-Z.; Lv, G.-F.; Hu, M.; Li, Y.; Li, J.-H. Chin. Chem. Lett. 2023, 34, 108590.

DOI

[13]
Hang, Z.; Xu, T.; Ju, C.; Gao, C.; Loh, T.-P.; Xie, P. Green Synth. Catal. 2025, 10.1016/j.gresc.2025.03.002.

[14]
Li, L.; Yang, G.; Xiong, T.; Duan, T.; Wang, J.; Wang, X. Chin. Chem. Lett. 2025, 36, 111374.

DOI

[15]
Lu, W.; Li, W.; Zhou, Y.; Xie, Y.; Chen, W. Chin. Chem. Lett. 2022, 33, 4865.

DOI

[16]
(a) Pu, G.; Song, S.-Y.; Yang, J.; Guo, P.; Jia, J.; Liu, P.; Li, X.; Liu, P.; He, C.-Y. Org. Chem. Front. 2024, 11, 3320.

DOI

(b) Chen, M.; Wang, C.; Xie, L.; Mao, T.; Xiao, L.; Wang, Z.; Han, W.-Y.; Liu, P.; Jia, J. Org. Biomol. Chem. 2025, 23, 2445.

DOI PMID

[17]
Deng, Y.; Huang, J.; Qian, Y.; Sun, Z.; Huang, Q.; Cao, S. Chem. Asian J. 2024, 19, e202400698.

[18]
Huang, M.-Z.; Xiao, L.-X.; Zhang, X.-G.; Song, X.-F.; Tu, H.-Y. Org. Lett. 2025, 27, 7137.

DOI

[19]
Zeng, Q.; Liu, Y.; He, J.; Deng, Y.; Zheng, P.; Sun, Z.; Cao, S. Org. Biomol. Chem. 2023, 21, 4982.

DOI

[20]
Zhu, X.; Xie, Z.; Chen, X.; Mu, M.; Wu, H.; Sun, M.; Yang, J.; Wang, L.; Wang, Z. J. Org. Chem. 2024, 89, 14940.

DOI

Outlines

/

〈 〉